AstraZeneca Reverses Investment Pause with £300 Million UK Commitment

On 29 April 2026 AstraZeneca pledged £300 million to the UK, restoring a £200 million Cambridge expansion and adding £100 million for a ‘lab of the future’ at Macclesfield, which will use digital tools; Cambridge work will finish the Rosalind Franklin building. Starmer said the plan will future-proof up to 1,000 jobs.

The Guardian

After pausing the Cambridge expansion and cancelling a £450 million Speke vaccine plant in 2025 over limited government support, AstraZeneca reversed course after a UK-US pharmaceutical arrangement (April 2026) aligned NHS drug prices with US levels and granted tariff-free US drug access.

Astrazeneca ploughs £300m into UK in surprise U-turn

Key participants include AstraZeneca CEO Pascal Soriot, Prime Minister Keir Starmer, Science Secretary Liz Kendall, ABPI chief Richard Torbett, plus Merck (which withdrew a £1 billion London hub) and Boehringer Ingelheim (which announced a £150 million AI centre in King’s Cross).

Pharmaphorum

AstraZeneca posted an 8 % Q1 revenue rise to $15.3 billion, with 16 % oncology and 15 % rare-disease growth. Cancer drugs now account for nearly half of sales; the firm targets 25 blockbusters and $80 billion in sales by 2030.

The Guardian

Starmer credited the US-UK arrangement for the investment; Soriot thanked the government for drug approvals; Kendall called the funding a “significant vote of confidence”; Torbett noted 13 pharma commitments totalling £1.575 billion since the deal.

Pharmaphorum

AZ warned Europe could miss medicines under most-favoured-nation pricing; Soriot criticised the UK regulatory regime and cautioned that without reform the region may lose R&D, access and manufacturing; Merck’s hub withdrawal signals investor scepticism. AstraZeneca did not disclose Macclesfield job numbers, and sources differ on whether US-UK deal is framed mainly as a Trump-era pricing alignment or a broader pharmaceutical arrangement.

Bloomberg

The £300 million injection bolsters the UK life-science hub and may attract investment, while the pricing alignment could raise NHS drug costs and affect European market access. AstraZeneca aims to finish the Rosalind Franklin building by 2027 and launch the Macclesfield lab thereafter. Government will monitor the US-UK arrangement’s impact on pricing, access and future investment pipelines.

Reuters

• “I can announce a significant new investment by AstraZeneca, investing 300 million pounds in UK life sciences, made possible by the pharmaceutical arrangement we have struck with the United States,” — Keir Starmer, Prime Minister

Reuters

• “for their effort to improve access for patients, including four new [drug] approvals since the beginning of the year, and we look forward to further enhancing the access and the reimbursement environment and build a strong life sciences sector” — Pascal Soriot, CEO, AstraZeneca

The Guardian

• “This investment is another significant vote of confidence in our science community and backs British research to do what it does best – develop the drugs, treatments and innovations that improve lives.” — Liz Kendall, Science Secretary

The Guardian

• “When companies believe that the medicines they develop will be properly valued and made available to NHS patients, they invest.” — Richard Torbett, CEO, ABPI

Pharmaphorum